Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: A cohort study using the United Network for Organ Sharing registry

Liver Transplantation

Volumn 20, Issue 9, 2014, Pages 1045-1056

  Schlansky, Barry ^a   Chen, Yiyi ^b   Scott, David L ^a   Austin, Donald ^b   Naugler, Willscott E ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Department of Public Health and Preventive Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; PREDICTION; PRIORITY JOURNAL; REGISTER; RISK FACTOR; SURVIVAL; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; DONOR; EPIDEMIOLOGY; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HOSPITAL ADMISSION; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; SUPPLY AND DISTRIBUTION; TIME; TIME TO TREATMENT; TRANSPLANTATION; TREATMENT OUTCOME; UNITED STATES;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; TIME FACTORS; TIME-TO-TREATMENT; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TREATMENT OUTCOME; UNITED STATES; WAITING LISTS;

EID: 84906937430     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23917     Document Type: Article

References (46)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Altekruse SF, McGlynn KA, Reichman ME,. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491.
3. Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2008; 15: 1001-1007.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
5. Hayashi PH, Trotter JF, Forman L, Kugelmas M, Steinberg T, Russ P, et al. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadaveric liver allocation in the era of MELD. Liver Transpl 2004; 10: 42-48.
6. Bruix J, Fuster J, Llovet JM,. Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transpl 2003; 9: 700-702.
7. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A,; for OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-e22.
8. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, Busuttil RW,. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008; 143: 182-188.
9. Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J, Merion RM,. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era. Dig Dis Sci 2012; 57: 806-812.
10. Biggins SW,. Futility and rationing in liver retransplantation: when and how can we say no? J Hepatol 2012; 56: 1404-1411.
11. Schwartz M, Roayaie S, Llovet J,. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol 2005; 43: 584-589.
12. Ioannou GN, Perkins JD, Carithers RL Jr,. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008; 134: 1342-1351.
13. Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-1267.
14. Yao FY, Hirose R, LaBerge JM, Davern TJ III, Bass NM, Kerlan RK Jr, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005; 11: 1505-1514.
15. Yao FY, Kerlan RK Jr, Hirose R, Davern TJ III, Bass NM, Feng S, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48: 819-827.
16. Roberts JP, Venook A, Kerlan R, Yao F,. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transpl 2010; 16: 925-929.
17. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16: 262-278.
18. Washburn K, Edwards E, Harper A, Freeman R,. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010; 10: 1643-1648.
19. Wiesner RH, Freeman RB, Mulligan DC,. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004; 127 (suppl 1): S261-S267.
20. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002; 8: 873-883.
21. Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using Organ Procurement Transplant Network data. Liver Transpl 2009; 15: 859-868.
22. Toso C, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T, et al. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology 2012; 56: 149-156.
23. Keller EJ, Kwo PY, Helft PR,. Ethical considerations surrounding survival benefit-based liver allocation. Liver Transpl 2014; 20: 140-146.
24. Neuberger J,. Liver allocation for patients with hepatocellular carcinoma. Liver Transpl 2010; 16: 249-251.
25. Persad G, Wertheimer A, Emanuel EJ,. Principles for allocation of scarce medical interventions. Lancet 2009; 373: 423-431.
26. Organ Procurement and Transplantation Network. Policy 3.6: allocation of livers. http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy- 8.pdf. Accessed July 2013.
27. Organ Procurement and Transplantation Network. Citing data. http://optn.transplant.hrsa.gov/data/citing.asp. Accessed July 2013.
28. Social Security Death Master File. http://www.ssdmf.com/FolderID/54/ SessionID/%7BA32A139E-72F3-4375-B508-B3E00C201793%7D/PageVars/Library/ InfoManage/Guide.htm. Accessed July 2013.
29. Kemmer N, Neff G, Kaiser T, Zacharias V, Thomas M, Tevar A, et al. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma. Liver Transpl 2006; 12: 1519-1522.
30. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM,. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8: 419-425.
31. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-790.
32. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
33. Asrani SK, Kim WR, Edwards EB, Larson JJ, Thabut G, Kremers WK, et al. Impact of the center on graft failure after liver transplantation. Liver Transpl 2013; 19: 957-964.
34. Freeman RB, Mithoefer A, Ruthazer R, Nguyen K, Schore A, Harper A, Edwards E,. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl 2006; 12: 1504-1511.
35. Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-279.
36. Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS Jr, et al.; for A2ALL Study Group. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007; 7: 1601-1608.
37. Kulik LM, Fisher RA, Rodrigo DR, Brown RS Jr, Freise CE, Shaked A, et al.; for A2ALL Study Group. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant 2012; 12: 2997-3007.
38. Bittermann T, Niu B, Hoteit MA, Goldberg D,. Waitlist priority for hepatocellular carcinoma beyond Milan criteria: a potentially appropriate decision without a structured approach. Am J Transplant 2014; 1: 79-87.
39. Kalager M, Adami HO, Bretthauer M, Tamimi RM,. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med 2012; 156: 491-499.
40. Yao FY,. Liver transplantation for hepatocellular carcinoma: the hepatitis C quandary. Liver Transpl 2007; 13: 783-785.
41. Bozorgzadeh A, Orloff M, Abt P, Tsoulfas G, Younan D, Kashyap R, et al. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Liver Transpl 2007; 13: 807-813.
42. Dumitra S, Alabbad SI, Barkun JS, Dumitra TC, Coutsinos D, Metrakos PP, et al. Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience. HPB (Oxford) 2013; 15: 724-731.
43. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA,. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307-313.
44. Heimbach J, Hirose R, Olthoff K, Kim W, Schladt D, Xiong H, et al. Delaying HCC MELD exception score improves disparity in access to liver transplant [abstract]. http://www.atcmeetingabstracts.com/abstract/delayed-hcc- meld-exception-score-improves-disparity-in-access-to-liver-transplant. Accessed January 2014.
45. OPTN/UNOS Liver and Intestinal Organ Transplantation Committee. Conference call interim report. June 20, 2013, 12:00pm EDT. http://optn. transplant.hrsa.gov/CommitteeReports/interim-main- Liver&IntestinalOrganTransplantationCommittee-7-22-2013-15-44.pdf. Accessed January 2014.
46. Hermansen SW, Leitzmann MF, Schatzkin A,. The impact on National Death Index ascertainment of limiting submissions to Social Security Administration Death Master File matches in epidemiologic studies of mortality. Am J Epidemiol 2009; 169: 901-908.